We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Prostate Cancer Drugs Undergoing FDA Safety Review for CV Risks
The item has been added to your shopping cart.
Prostate Cancer Drugs Undergoing FDA Safety Review for CV Risks
May 3, 2010
The FDA is conducting a safety review of a class of commonly used prostate cancer drugs in light of a safety signal showing they may pose a small increased
risk for diabetes and cardiovascular (CV) disease in men treated with the medications.